Nova Mentis receives approval for autism clinical study

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

Are psychedelics the future of autism treatment? Nova Mentis Life Sciences Corp. (NOVA) received Canadian approval for a new study on autism, which will be the first step in bringing psilocybin treatment to autistic patients. Researchers will observe 200 patients with autism spectrum disorder (ASD) or fragile x syndrome (FXS) to establish baseline biomarkers that can be used to measure psilocybin treatment responses in a later study. NOVA will monitor the gut microbiome, immune response, and serotonin activity in patients, as these factors influence behavioural symptoms.

PDF of article